1. 1) DeNardo, G. L., DeNardo, S. J., Goldstein, D. S., Kroger, L. A., Lamborn, K. R., Levy, N. B., McGahan, J. P., Salako, Q., Shen, S. and Lewis, J. P.: Maximum-tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma, J. Clin. Oncol., 16, 3246-3256 (1998)
2. 2) Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., and Fisher, S.: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma, J. Clin. Oncol., 14, 1974-1981 (1996)
3. 3) Knox, S. J., Goris, M. L., Trisler, K., Negrin, R., Davis, T., Liles, T-M., Grillo-Lopez, A. J., Chinn, P., Varns, C. and Nings, S-C.: Yttrium-90-lableled anti- CD20 monoclonal antibody therapy of recurrent B-cell lymphoma, Clin. Cancer Res., 2, 457-470 (1996)
4. 4) Juweid, M., Sharkey, R. M., Markowitz, A., Behr, T. M., Swayne, L. C., Dunn, R., Hansen, H. J., Shevitz, J., Leung, S. O. and Rubin, A. D., Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody, Cancer Res., 55, 5899-5907 (1995)
5. 5) Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Nelp, W. B., Glenn, S., Fisher, D. R., Porter, B., Matthews, D. C. and Gooley, T.: Phase II trial of I-131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas, Lancet, 346, 336-340 (1995)